Chloramphenicol + Beclomethasone Dipropionate + Clotrimazole + Lidocaine HydrochlorideThird Party Manufacturing in India

Chloramphenicol + Beclomethasone Dipropionate + Clotrimazole + Lidocaine Hydrochloride works via a multi-targeted mechanism to resolve complex ear infections. Chloramphenicol inhibits bacterial protein synthesis, clotrimazole disrupts fungal cell membrane permeability, beclomethasone suppresses localized inflammatory cytokines, and lidocaine blocks voltage-gated sodium channels to eliminate pain transmission. Together, they act on these multiple cellular pathways to help the body eradicate mixed ear infections and swelling. Unlike single-ingredient drops, this complex formulation resolves pain, infection, and inflammation simultaneously. It is highly effective and well-tolerated.

Therapeutic Uses

• Mixed Otitis Externa: Indicated for the comprehensive treatment of acute ear infections complicated by simultaneous bacterial and fungal colonization.
• Otomycosis accompanied by Pain: Prescribed to relieve severe inflammation, itching, and acute pain in the external ear canal.

Why Manufacturers Choose Chloramphenicol + Beclomethasone Dipropionate + Clotrimazole + Lidocaine Hydrochloride

Chloramphenicol + Beclomethasone Dipropionate + Clotrimazole + Lidocaine Hydrochloride third party manufacturing in India is highly valued by ENT specialists as a definitive first-line empirical cure for painful ear conditions. Celesta utilizes high-tier partner facilities that are WHO-GMP certified to carefully blend these four distinct active ingredients into a stable non-aqueous or aqueous base. Adding this quad-action medical product to your catalog guarantees high prescription volume from practicing clinics seeking WHO-GMP validated formulations.